Cargando…

MYCN Drives a Tumor Immunosuppressive Environment Which Impacts Survival in Neuroblastoma

A wide range of malignancies presents MYCN amplification (MNA) or dysregulation. MYCN is associated with poor prognosis and its over-expression leads to several dysregulations including metabolic reprogramming, mitochondria alteration, and cancer stem cell phenotype. Some hints suggest that MYCN ove...

Descripción completa

Detalles Bibliográficos
Autores principales:	Raieli, Salvatore, Di Renzo, Daniele, Lampis, Silvia, Amadesi, Camilla, Montemurro, Luca, Pession, Andrea, Hrelia, Patrizia, Fischer, Matthias, Tonelli, Roberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7951059/ https://www.ncbi.nlm.nih.gov/pubmed/33718189 http://dx.doi.org/10.3389/fonc.2021.625207

Ejemplares similares

MYCN Impact on High-Risk Neuroblastoma: From Diagnosis and Prognosis to Targeted Treatment
por: Bartolucci, Damiano, et al.
Publicado: (2022)

The MYCN inhibitor BGA002 restores the retinoic acid response leading to differentiation or apoptosis by the mTOR block in MYCN-amplified neuroblastoma
por: Lampis, Silvia, et al.
Publicado: (2022)

Antigene MYCN Silencing by BGA002 Inhibits SCLC Progression Blocking mTOR Pathway and Overcomes Multidrug Resistance
por: Bortolotti, Sonia, et al.
Publicado: (2023)

An ALYREF-MYCN coactivator complex drives neuroblastoma tumorigenesis through effects on USP3 and MYCN stability
por: Nagy, Zsuzsanna, et al.
Publicado: (2021)

MYCN drives glutaminolysis in neuroblastoma and confers sensitivity to an ROS augmenting agent
por: Wang, Tingting, et al.
Publicado: (2018)

The super elongation complex drives transcriptional addiction in MYCN-amplified neuroblastoma
por: Wang, Donghai, et al.
Publicado: (2023)

MYCN Function in Neuroblastoma Development
por: Otte, Jörg, et al.
Publicado: (2021)

MYCN and Metabolic Reprogramming in Neuroblastoma
por: Bansal, Mohit, et al.
Publicado: (2022)

Metastasis in neuroblastoma: the MYCN question
por: Bhavsar, Swapnil Parashram
Publicado: (2023)

Ferroptosis vulnerability in MYCN‐driven neuroblastomas
por: Dasgupta, Shayani, et al.
Publicado: (2022)

MYCN Amplifications and Metabolic Rewiring in Neuroblastoma
por: Pouliou, Marialena, et al.
Publicado: (2023)

Implementation of the plasma MYCN/NAGK ratio to detect MYCN amplification in patients with neuroblastoma
por: Su, Yan, et al.
Publicado: (2020)

MYCN upregulates the transsulfuration pathway to suppress the ferroptotic vulnerability in MYCN-amplified neuroblastoma
por: Floros, Konstantinos V., et al.
Publicado: (2022)

MYCN is a novel oncogenic target in pediatric T-cell Acute Lymphoblastic Leukemia
por: Astolfi, Annalisa, et al.
Publicado: (2013)

Exploitation of chick embryo environments to reprogram MYCN-amplified neuroblastoma cells to a benign phenotype, lacking detectable MYCN expression
por: Carter, R, et al.
Publicado: (2012)

MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma
por: Agarwal, Saurabh, et al.
Publicado: (2018)

Therapeutic potential of targeting MYCN: A case series report of neuroblastoma with MYCN amplification
por: Huang, Can, et al.
Publicado: (2020)

A MYCN-independent mechanism mediating secretome reprogramming and metastasis in MYCN-amplified neuroblastoma
por: Zhang, Hai-Feng, et al.
Publicado: (2023)

Regulation of MYCN expression in human neuroblastoma cells
por: Jacobs, Joannes FM, et al.
Publicado: (2009)

MYCN and mutationally activated ALK synergise in neuroblastoma
Publicado: (2012)

MYCN amplification and ATRX mutations are incompatible in neuroblastoma
por: Zeineldin, Maged, et al.
Publicado: (2020)

MYCN in Neuroblastoma: “Old Wine into New Wineskins”
por: Braoudaki, Maria, et al.
Publicado: (2021)

Targeting MYCN and ALK in resistant and relapsing neuroblastoma
por: Tucker, Elizabeth R, et al.
Publicado: (2019)

The MicroRNA Landscape of MYCN-Amplified Neuroblastoma
por: Misiak, Danny, et al.
Publicado: (2021)

MYCN is an immunosuppressive oncogene dampening the expression of ligands for NK-cell-activating receptors in human high-risk neuroblastoma
por: Brandetti, Elisa, et al.
Publicado: (2017)

Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study
por: Berbegall, Ana P., et al.
Publicado: (2018)

MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis
por: Alborzinia, Hamed, et al.
Publicado: (2022)

MYCN is amplified during S phase, and c-myb is involved in controlling MYCN expression and amplification in MYCN-amplified neuroblastoma cell lines
por: Aygun, Nevim, et al.
Publicado: (2019)

MYCN-targeting miRNAs are predominantly downregulated during MYCN-driven neuroblastoma tumor formation
por: Beckers, Anneleen, et al.
Publicado: (2014)

Correction: MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma
por: Agarwal, Saurabh, et al.
Publicado: (2018)

Elimination of MYCN-Amplified Neuroblastoma Cells by Telomerase-Targeted Oncolytic Virus via MYCN Suppression
por: Tanimoto, Terutaka, et al.
Publicado: (2020)

Genomic profile of MYCN non-amplified neuroblastoma and potential for immunotherapeutic strategies in neuroblastoma
por: Lee, Eunjin, et al.
Publicado: (2020)

On the significance of germline cytogenetic rearrangements at MYCN locus in neuroblastoma
por: Lipska, Beata S, et al.
Publicado: (2013)

MYCN induces neuroblastoma in primary neural crest cells
por: Olsen, R R, et al.
Publicado: (2017)

Precision Anti-Cancer Medicines by Oligonucleotide Therapeutics in Clinical Research Targeting Undruggable Proteins and Non-Coding RNAs
por: Bartolucci, Damiano, et al.
Publicado: (2022)

FOXR2 Stabilizes MYCN Protein and Identifies Non–MYCN-Amplified Neuroblastoma Patients With Unfavorable Outcome
por: Schmitt-Hoffner, Felix, et al.
Publicado: (2021)

SMAD9-MYCN positive feedback loop represents a unique dependency for MYCN-amplified neuroblastoma
por: Tan, Kezhe, et al.
Publicado: (2022)

MYCN amplification confers enhanced folate dependence and methotrexate sensitivity in neuroblastoma
por: Lau, Diana T., et al.
Publicado: (2015)

The Mechanism by Which MYCN Amplification Confers an Enhanced Sensitivity to a PCNA-Derived Cell Permeable Peptide in Neuroblastoma Cells
por: Gu, Long, et al.
Publicado: (2015)

Correlation Between MYCN Gene Status and MYCN Protein Expression in Neuroblastoma: A Pilot Study To Propose the Use of MYCN Immunohistochemistry in Limited-Resource Areas
por: Santiago, Teresa, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_u9bfmgmbuljqsi58vcob1bapmd